23andMe, once valued at $6B, is now a penny stock. CEO Anne Wojcicki discusses the company's challenges, goals, and price increases. The WSJ explores what went wrong and the future of genetic testing. Tune in to the David Rubenstein Show for Anne's insights on her company and the industry.